Mixed connective tissue disease Future or Investigational Therapies
|
Mixed connective tissue disease Microchapters |
|
Differentiating Mixed connective tissue disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mixed connective tissue disease Future or Investigational Therapies On the Web |
|
American Roentgen Ray Society Images of Mixed connective tissue disease Future or Investigational Therapies |
|
FDA on Mixed connective tissue disease Future or Investigational Therapies |
|
on Mixed connective tissue disease Future or Investigational Therapies |
|
Mixed connective tissue disease Future or Investigational Therapies in the news |
|
Blogs onMixed connective tissue disease Future or Investigational Therapies |
|
Directions to Hospitals Treating Mixed connective tissue disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rate have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.
Future or Investigational Therapies
- MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rate have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.[1]
References
- ↑ Reiseter S, Gunnarsson R, Corander J, Haydon J, Lund MB, Aaløkken TM, Taraldsrud E, Hetlevik SO, Molberg Ø (December 2017). "Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study". Arthritis Res. Ther. 19 (1): 284. doi:10.1186/s13075-017-1494-7. PMC 5740892. PMID 29268795.